Summary The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats. D-Trp6-LH-RH microcapsules were injected once a month for 3 months, in a dose calculated to release 25 jg day-. Control animals received the injection vehicle. Sixty days after the first injection of microcapsules, cyclophosphamide was given at a loading dose of 50mgkg-' followed by 5 mg kg-' day-' for 30 days, while the treatment with D-Trp6-LH-RH was continued. When the ovaries were examined 3 months and 5 months after discontinuation of treatment, a significant reduction in the total number of follicles (P<0.01) was found in non-pretreated animals given cyclophosphamide. This reduction affected mainly follicles larger than 100 .tm. An irreversible disintegration and destruction of granulosa cells was also observed in this group. In animals pretreated with D-Trp6-LH-RH, administration of cyclophosphamide caused no reduction in the number and diameter of follicles. Thus, the treatment with D-Trp6-LH-RH microcapsules before and during chemotherapy prevented the ovarian injury inflicted by cyclophosphamide. The suppression of gonadal function by LH-RH analogues could be possibly utilised for the protection of the ovaries against damage caused by cytotoxic drugs.
The administration of cytotoxic drugs such as cyclophosphamide, chlorambucil, vincristine, procarbazine, busulphan and others may cause amenorrhoea in women and inhibit spermatogenesis in men (Damewood & Grochow, 1986; Gradisher & Schilsky, 1988 ; Rivkees & Crawford, 1988) . These agents are commonly used in the treatment of malignant diseases such as Hodgkin's disease and leukaemia. Cyclophosphamide has been likewise used in the treatment of nephrotic syndrome, various forms of glomerulonephritis and connective tissue diseases and for the control of organ rejection after transplantation (Gradishar & Schilsky, 1988) . Samaan et al. (1978) also reported that amenorrhoea that developed in 70% of premenopausal patients with breast cancer after adjuvant chemoimmunotherapy consisting of 5-fluorouracil, adriamycin, cyclophosphamide and BCG was a result of primary ovarian failure. Frequently, cytotoxic therapy has to be used in young people in whom the preservation of gonadal function and fertility is important.
The incidence of gonadal dysfunction in patients treated with cytotoxic drugs varies according to pubertal state, sex, and type of chemotherapeutic regimen. Patients treated during adulthood have the highest incidence of gonadal dysfunction, whereas subjects treated during the prepubertal stage are less affected by chemotherapy (Damewood & Grochow, 1986; Rivkees & Crawford, 1988) .
Since cytotoxic drugs affect more tissues with a rapid cellular turnover, it has been suggested that a state of induced gonadal inhibition during the exposure to chemotherapy may protect the gonads (Karashima et al., 1988; Rivkees & Crawford, 1988) . Chronic administration of agonists of luteinising hormone releasing hormone (LH-RH), after an initial period of stimulation, induces downregulation of the receptors, desensitisation of pituitary gonadotrophs and suppression of the gonadal functions (Schally et al., 1980; Schally, 1989) . This inhibitory effect is reversible, and gonadal recovery occurs after treatment with LH-RH agonists is discontinued. This approach has been suggested as a possible protective method against gonadal damage induced by chemotherapeutic drugs and radiation (Glode et al., 1982; Jarrel et al., 1987b; Karashima et al., 1988; Lewis et al., 1985; Schally et al., 1987; Schally, 1989) .
Recently, we have developed long-acting delivery systems of D-Trp6-LH-RH (Schally, 1989; Mason-Garcia et al., 1985) . Microcapsule or microparticle formulations release therapeutic concentrations of this analog for 30 days or longer after intramuscular injection (Bokser et al., 1989; Mason-Garcia et al., 1985) . This continuous-release formulation of LH-RH agonists is much more efficacious than daily injections (Bokser et al., 1989 ).
Testes show a higher incidence of chemotherapy-induced damage (Rivkees & Crawford, 1988; Wang et al., 1980) . However, the incidence of ovarian dysfunction after chemotherapy can reach 80% among women treated for Hodgkin's disease (Chapman et al., 1979) . Several studies on gonadal protection against the damage induced by cytotoxic drugs have been performed in males of different species (Glode et al., 1982; Karashima et al., 1988; Lewis et al., 1985; Nseyo et al., 1985) , but the information about females is limited. Ataya et al. (1985) reported that administration of the LH-RH agonist D-Leu6-des-Gly'0-NH2-LH-RH ethylamide before and during chemotherapy was able to prevent the ovarian follicle loss induced by cyclophosphamide in the rat. The evaluation was performed immediately after the cessation of cyclophosphamide administration, and women submitted to chemotherapeutic drugs may progress after several months or several years from a condition of fertility and normal menses to sterility and premature menopause (Chapman et al., 1979 Three and five months after the last injection of cyclophosphamide, four to nine animals from each group were killed. Since most of the rats in the cyclophosphamide treated group stopped cycling and were in permanent oestrus, all the cycling animals in other groups were killed on the day of oestrus. Blood was collected for hormone determination and ovaries were removed, weighed and prepared for histological examination.
Histological procedures
The ovaries were fixed in 10% neutral buffered formalin and embedded into paraplast; 6 lm thick sections were cut and stained with hematoxylin and eosin. One ovary of each animal was examined. Every fortieth section was examined using a light microscope (Leitz Diaplan equipped with a calibrated ocular micrometre net). Follicles with a nucleolus in the oocyte were counted. The total number of follicles was estimated using the method of Dornfeld et al. (1942) . The diameter of the follicles was determined as the mean of the longest and shortest diameter of each follicle measured as a straight-line distance between opposite points of the basement membrane. Measurements were carried out with the ocular micrometre net.
Hormone determination Serum LH and FSH were determined by specific radioimmunoassay (RIA) using materials supplied by the National Hormone and Pituitary Program (NHPP) (Niswender et al., 1968) . Oestradiol was extracted from serum and measured using a kit provided by Radioassay System Laboratories Inc. (Carson, CA, USA) (Abraham, 1974) . All samples for each hormone at 3 months and 5 months after discontinuation of treatment were analysed in the same assays. The intra and inter-assay coefficient of variation were less than 10% and 15% respectively for these assays. Results are expressed as mean ± s.e.m.
Statistical significance was assessed by Duncan's new multiple range test using a computer program (Redding & Schally, 1983) .
Results
Three months after discontinuation of treatment, the rats receiving cyclophosphamide alone, had lower body weights than the controls (P<0.01), while the animals treated with D-Trp6-LH-RH microcapsules or with the combination showed increases in body weights (P<0.01 and P<0.05 respectively) ( Table I) . A marked decrease in the ovarian weight was seen in all of the treated groups (P<0.01) ( Table  I ). The treatment with cyclophosphamide alone induced a significant reduction in the total number of follicles (P<0.01) ( Table I ). This reduction affected mainly follicles with a diameter larger than 30 1tm, with an almost complete disappearance of follicles larger than 200 gm (Figure 1 ). In the groups receiving microcapsules or the combination, the total number of follicles was higher than in the controls (P<0.05 and P<0.01 respectively) ( Table I) . This difference was mainly due to follicles sized between 100 and 200 gm ( Figure  1 ). In the cyclophosphamide treated group, several follicles showed an irreversible disintegration and destruction of the granulosa cells (Figure 2a ). Although this phenomenon was observed also in some of the animals treated with the combination, it was reversible and no damage was found at the end of the experiment (Figure 2b ). In the animals treated only with cyclophosphamide, the LH serum levels were lower than in the controls (P<0.01), while the rats treated with the LH-RH analogue or with the combination showed no differences with respect to the untreated group. There was no significant differences in FSH levels between treated and untreated groups (Table I) .
Five months after cessation of treatment, the body weights of the cyclophosphamide treated animals remained significantly lower than in controls (P<0.05), while no differences were observed in the D-Trp6-LH-RH microcapsules or in the combination treated groups (Table II) . At this time, the ovarian weights were similar in the four groups. However, the total number of follicles and the diameter of follicles in the rats treated only with cytoxan were smaller (P<0.05 and 0.01, respectively) (Table II) . When the number of follicles was evaluated according to their diameter, the follicles sized 200 im or larger had virtually disappeared in the group given cytoxan alone (Figure 3) . The number and diameter of the follicles in the groups given D-Trp6-LH-RH alone or in combination with cytoxan were similar to those of controls (Table II) .
Cyclophosphamide treated rats showed LH levels lower than the controls (P<0.01), but the group given microcapsules and the combination group showed normal levels. There were no significant differences in the FSH levels between treated and untreated groups. In the cyclophosphamide treated animals, the oestradiol levels were significantly lower than in controls (P<0.05) (Table II) . Chapman and Sutcliffe (1981) found that the administration of oral contraceptives to women treated with cytotoxic drugs protected the ovaries against the injury caused by these agents. However, the use of oestrogen and progestin in patients submitted to chemotherapy could be hazardous (Ataya et at., 1985) . Recently, Ataya et al. (1985) reported that the agonist D-Leu6-des-Gly'0NH2-LH-RH ethylamide prevented the follicular loss produced immediately after the cessation of cyclophosphamide administration in rats, through the inhibition of the process of recruitment of small follicles into the pool of larger follicles. The damage induced by cytotoxic drugs is dependent on chemotherapeutic regimen and the dose administered (Damewood & Grochow, 1986; Rivkees & Crawford, 1988) . It has been reported that 49% of patients treated for Hodgkin's disease became amenorrhoeic, 34% showed irregular menstrual cycles and only 17% exhibited a normal ovarian function immediately after the therapy (Chapman et al., 1979) . Moreover, after 16 months of follow-up, 30% or the women with normal and irregular menstrual cycles showed a progressive loss of ovarian function (Chapman et al., 1979) . This indicates that Azgly'°-LH-RH ethylamide to rats produced inhibition of the ovarian 3H-thymidine uptake, which is an index of mitotic ovarian activity (Ataya et al., 1988) . The number of granulosa cells per follicle has been directly correlated with the follicular diameter (Hirschfield & Midgley, 1978 (Vickery, 1986) , the optimal dosage and duration of pretreatment with the agonists must be the subject of additional investigations before any possible clinical trials.
In spite of the evidence of ovarian damage in the group treated with cyclophosphamide alone, as manifested by reduction in the ovarian weight, decrease in the number of follicles and a fall in serum oestradiol, there was no elevation in serum gonadotrophin levels. Similar results were reported by Jarrel et al. (1987a) . This suggests a possible cytotoxic effect of cyclophosphamide on the hypothalamo-pituitary axis leading to a reduction in gonadotrophin secretion. Weight loss and chronic stress could be also involved in these phenomena (Frisch & McArther, 1974; Hulse et al., 1982) . Although the initial differentiation of somatic elements into follicular cells occurs even in the absence of circulating gonadotrophin, normal development of medium sized to large follicles depends on gonadotrophic stimulation (Hardy et al., 1974; Lunenfeld et al., 1975) . Interference with the pituitary secretion could be an additional mechanism responsible for gonadal failure seen in these animals. Since no alterations were detected in the pituitary-gonadal axis in the group treated with the combination as compared to controls, it is feasible that the functional inhibition of the pituitary gonadotrophs produced by the LH-RH agonist, protects the hypophyseal cells against a possible damage inflicted by cyclophosphamide.
As expected, the animals treated with cyclophosphamide alone showed a marked decrease in their body weight (Ataya et al., 1985; Jarrel et al., 1987a) , while the rats receiving only D-Trp6-LH-RH exhibited a significant increase, which could be attributed to the pharmacological castration produced by the LH-RH agonists (Bokser et al., 1989) . The group treated with the combination also showed an augmentation in the body weight as compared to controls. This raises an intriguing possibility that other organs may have been protected against the toxic effects of cyclophosphamide. However, no differences were found in peripheral white blood cell count (WBC) between the groups treated with cyclophosphamide alone or in combination with D-Trp6-LH-RH, the WBC of both groups being lower than in untreated controls (data not shown). This indicates that the analogue was unable to prevent the toxic effects of cyclophosphamide on the bone marrow. Ataya et al. (1988) showed that, in contrast to the ovary, the treatment with an LH-RH agonist did not inhibit mitotic activity in the duodenum, skeletal muscle or bone marrow. Further investigations are necessary in order to evaluate a possible systemic protection against the deleterious actions of cytotoxic drugs.
It was interesting that 3 months after the treatment, the groups receiving D-Trp6-LH-RH microcapsules or the combination with cyclophosphamide exhibited a higher number of follicles per ovary than the control group. Hypophysectomy also retards the rate at which the oocytes disappear from the ovaries in mice (Jones & Krohn, 1961) . This suggests that the inhibition of the gonadotrophin secretion induced by LH-RH agonists is also able to retard the normal process of progressive loss of oocytes caused by the natural mechanism of aging (Ataya et al., 1989) .
Whereas repeated administration of LH-RH agonists is required to reduce the levels of LH, FSH and sex steroids, an immediate inhibition can be obtained after the first injection of LH-RH antagonists (Bajusz et al., 1988a, b; Schally et al., 1980; Schally, 1989; Vickery, 1986) . Recently, we have synthesised highly potent antagonists of LH-RH, free of sideeffects in animals and humans (Bajusz et al., 1988a,b; Gonzalez-Barcena et al., 1989; Schally, 1989) . In addition, we have developed prototypes of sustained delivery systems consisting of microcapsules of our LH-RH antagonist SB-75 (Csernus et al., 1990) . Since, in patients afflicted with a malignant disease, chemotherapy may have to be started soon after the diagnosis is made, LH-RH antagonists may be preferred over the agonists for induction of gonadal inhibition, considering the rapidity of their suppressive action (Karashima et al., 1988; Schally et al., 1980; Schally, 1989 
